trial · primary record
Acalabrutinib
Mantle Cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2027-07-13 |
| Primary endpoint | Incidence of unacceptable adverse events (AEs) (safety lead-in) |
| Registry ID | NCT06054776 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:33.100Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06054776
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.